Aclaris Therapeutics (ACRS) Reports Q2 Loss of $0.62/Share

Aclaris Therapeutics (NASDAQ: ACRS) reported Q2 EPS of ($0.62), versus ($1.52) reported last year.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

You May Also Be Interested In

• PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
• Exclusive: Axe Compute CEO says prepayments cover about a third of $3bn build cost
• JPMorgan Upgrades NAC Kazatomprom JSC (KAP:LI) to Overweight